anurajms/meta_analysis huggingface dataset:
MESH terms:
Strategies for enhancing the implementation of school‐based policies or practices targeting diet, physical activity, obesity, tobacco or alcohol use
1. *Diet; 2. Exercise; 3. *Nicotiana; 4. Obesity [prevention & control]; 5. Policy; 6. Randomized Controlled Trials as Topic; 7. Tobacco Use;
MESH terms:
Memantine for autism spectrum disorder
1. *Autism Spectrum Disorder [drug therapy]; 2. *Memantine [therapeutic use]; 3. Odds Ratio; 4. Outcome Assessment, Health Care; 5. Randomized Controlled Trials as Topic; 6. Treatment Outcome;
MESH terms:
Probiotics for preventing acute upper respiratory tract infections
1. Anti-Bacterial Agents [therapeutic use]; 2. *Influenza Vaccines; 3. *Influenza, Human; 4. *Probiotics [therapeutic use]; 5. Randomized Controlled Trials as Topic; 6. *Respiratory Tract Infections [drug therapy, prevention & control];
MESH terms:
Psychological therapies for temporomandibular disorders (TMDs)
1. Behavior Therapy; 2. *Cognitive Behavioral Therapy [methods]; 3. Pain; 4. Pain Measurement; 5. Randomized Controlled Trials as Topic; 6. *Temporomandibular Joint Disorders [therapy];
MESH terms:
Physical activity and exercise training in cystic fibrosis
1. *Cystic Fibrosis [drug therapy]; 2. Exercise; 3. Forced Expiratory Volume; 4. Quality of Life;
MESH terms:
Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis
1. Administration, Inhalation; 2. *Anti-Bacterial Agents [administration & dosage, therapeutic use]; 3. *Cystic Fibrosis [complications, drug therapy]; 4. Lung; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Tobramycin [administration & dosage, therapeutic use];
MESH terms:
Anti‐IL‐5 therapies for asthma
1. Adrenal Cortex Hormones [therapeutic use]; 2. Antibodies, Monoclonal [therapeutic use]; 3. *Asthma [drug therapy]; 4. Chronic Disease; 5. Disease Progression; 6. *Quality of Life; 7. Randomized Controlled Trials as Topic;
MESH terms:
Child protection training for professionals to improve reporting of child abuse and neglect
1. *Child Abuse [diagnosis, prevention & control]; 2. Family; 3. Health Personnel; 4. *Mandatory Reporting; 5. Systematic Reviews as Topic;
MESH terms:
Short‐acting inhaled bronchodilators for cystic fibrosis
1. Administration, Inhalation; 2. *Bronchodilator Agents [therapeutic use]; 3. *Cystic Fibrosis [complications, drug therapy]; 4. Forced Expiratory Volume; 5. Muscarinic Antagonists;
MESH terms:
Exercise versus airway clearance techniques for people with cystic fibrosis
1. Anti-Bacterial Agents [therapeutic use]; 2. *Cystic Fibrosis [complications]; 3. Drainage, Postural [methods]; 4. Forced Expiratory Volume; 5. Mucociliary Clearance;
MESH terms:
Interventions to improve water, sanitation, and hygiene for preventing soil‐transmitted helminth infection
1. Ascaris lumbricoides; 2. Hygiene; 3. Observational Studies as Topic; 4. *Sanitation [methods]; 5. *Soil [parasitology]; 6. Water;
MESH terms:
Non‐pharmacological interventions for sleep promotion in hospitalized children
1. *Child, Hospitalized; 2. *Delirium [prevention & control]; 3. Intensive Care Units; 4. Randomized Controlled Trials as Topic; 5. Respiration, Artificial; 6. Sleep;
MESH terms:
Digital interventions to improve adherence to maintenance medication in asthma
1. Adrenal Cortex Hormones; 2. *Asthma [drug therapy]; 3. Forced Expiratory Volume; 4. Medication Adherence; 5. Quality of Life;
MESH terms:
Antibiotics for the induction and maintenance of remission in ulcerative colitis
1. Anti-Bacterial Agents [adverse effects]; 2. Anti-Inflammatory Agents, Non-Steroidal [adverse effects]; 3. *Colitis, Ulcerative [drug therapy]; 4. Mesalamine [adverse effects, therapeutic use]; 5. Remission Induction;
MESH terms:
Community‐based interventions for improving mental health in refugee children and adolescents in high‐income countries
1. Anxiety [diagnosis, therapy]; 2. Developed Countries; 3. *Mental Health; 4. Quality of Life; 5. *Refugees;
MESH terms:
Music therapy for autistic people
1. *Autistic Disorder [therapy]; 2. Bias; 3. *Music Therapy; 4. Odds Ratio; 5. Quality of Life;
MESH terms:
Care delivery and self‐management strategies for children with epilepsy
1. *Epilepsy [psychology, therapy]; 2. Medication Adherence; 3. Quality of Life; 4. Seizures; 5. Self Care; 6. *Self-Management; 7. Systematic Reviews as Topic;
MESH terms:
Probiotics for the prevention of Hirschsprung‐associated enterocolitis
1. Australia; 2. Diarrhea [prevention & control]; 3. *Enterocolitis [etiology, prevention & control]; 4. Odds Ratio; 5. *Probiotics [therapeutic use];
MESH terms:
Negative pressure wound therapy for surgical wounds healing by primary closure
1. Blister; 2. *Negative-Pressure Wound Therapy [methods]; 3. Pain; 4. Randomized Controlled Trials as Topic; 5. Seroma [epidemiology, etiology, prevention & control]; 6. *Soft Tissue Injuries; 7. *Surgical Wound [therapy]; 8. Surgical Wound Infection [epidemiology, prevention & control];
MESH terms:
Fortification of salt with iron and iodine versus fortification of salt with iodine alone for improving iron and iodine status
1. *Anemia, Iron-Deficiency [epidemiology, prevention & control]; 2. Hemoglobins; 3. *Iodine; 4. Iron; 5. *Iron Deficiencies; 6. Micronutrients; 7. Sodium Chloride; 8. Sodium Chloride, Dietary;
MESH terms:
Continuous positive airway pressure (CPAP) for acute bronchiolitis in children
1. *Bronchiolitis [drug therapy]; 2. *Continuous Positive Airway Pressure [adverse effects, methods]; 3. Oxygen; 4. Partial Pressure; 5. Respiration, Artificial; 6. United States;
MESH terms:
Prophylactic cyclo‐oxygenase inhibitor drugs for the prevention of morbidity and mortality in preterm infants: a network meta‐analysis
1. *Cyclooxygenase Inhibitors [adverse effects]; 2. *Infant, Premature; 3. Morbidity; 4. Network Meta-Analysis; 5. Pharmaceutical Preparations;
MESH terms:
Probiotics for treatment of chronic constipation in children
1. *Constipation [therapy]; 2. *Probiotics [adverse effects]; 3. Treatment Outcome;
MESH terms:
Unconditional cash transfers for reducing poverty and vulnerabilities: effect on use of health services and health outcomes in low‐ and middle‐income countries
1. *Developing Countries; 2. Health Services; 3. *HIV Infections [prevention & control]; 4. Outcome Assessment, Health Care; 5. Poverty;
MESH terms:
Oral dextrose gel for the treatment of hypoglycaemia in newborn infants
1. Breast Feeding; 2. Gels [therapeutic use]; 3. Glucose; 4. *Hypoglycemia [chemically induced, drug therapy]; 5. Hypoglycemic Agents [therapeutic use]; 6. Infant, Premature;
MESH terms:
Vitamin A supplementation for preventing morbidity and mortality in children from six months to five years of age
1. Diarrhea [chemically induced]; 2. Dietary Supplements; 3. *Measles [chemically induced, complications]; 4. Morbidity; 5. *Respiration Disorders; 6. Vitamin A [therapeutic use]; 7. *Vitamin A Deficiency [epidemiology, prevention & control];
MESH terms:
Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
1. Acetylcysteine; 2. Adrenal Cortex Hormones [therapeutic use]; 3. *Autoimmune Diseases [drug therapy]; 4. Cyclosporine [therapeutic use]; 5. Etanercept; 6. Immunoglobulins, Intravenous [therapeutic use]; 7. Observational Studies as Topic; 8. *Stevens-Johnson Syndrome [drug therapy]; 9. Thalidomide; 10. Tumor Necrosis Factor-alpha;
MESH terms:
Synbiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants
1. Enteral Nutrition [methods]; 2. *Enterocolitis, Necrotizing [etiology, prevention & control]; 3. *Fetal Diseases; 4. Infant, Extremely Premature; 5. *Infant, Newborn, Diseases; 6. Infant, Very Low Birth Weight; 7. *Synbiotics;
MESH terms:
Extended‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults
1. Anxiety Disorders [therapy]; 2. *Attention Deficit Disorder with Hyperactivity [drug therapy]; 3. *Central Nervous System Stimulants [adverse effects]; 4. *Methylphenidate [adverse effects]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic;
MESH terms:
Clonazepam monotherapy for treating people with newly diagnosed epilepsy
1. Anticonvulsants [adverse effects]; 2. Carbamazepine [therapeutic use]; 3. *Clonazepam [adverse effects]; 4. *Epilepsy [drug therapy]; 5. Seizures [drug therapy];
MESH terms:
Sealants for preventing dental caries in primary teeth
1. *Dental Caries [prevention & control]; 2. Dentition, Permanent; 3. Fluorides; 4. *Pit and Fissure Sealants [therapeutic use]; 5. Tooth, Deciduous;
MESH terms:
Binocular versus standard occlusion or blurring treatment for unilateral amblyopia in children aged three to eight years
1. *Amblyopia [therapy]; 2. Eyeglasses; 3. *Strabismus; 4. *Video Games; 5. Visual Acuity;
MESH terms:
Antiepileptic drugs for the primary and secondary prevention of seizures after stroke
1. Anticonvulsants [adverse effects]; 2. *Brain Ischemia; 3. Randomized Controlled Trials as Topic; 4. Secondary Prevention; 5. Seizures [drug therapy, etiology, prevention & control]; 6. *Stroke [drug therapy, prevention & control];
MESH terms:
Low‐carbohydrate versus balanced‐carbohydrate diets for reducing weight and cardiovascular risk
1. Body Weight; 2. Carbohydrates; 3. *Diet, Carbohydrate-Restricted; 4. *Energy Intake; 5. Heart Disease Risk Factors;
MESH terms:
Cuffed versus uncuffed endotracheal tubes for neonates
1. *Intubation, Intratracheal [adverse effects, instrumentation]; 2. Randomized Controlled Trials as Topic; 3. Respiratory Sounds; 4. Risk Assessment;
MESH terms:
Oral antihistamine‐decongestant‐analgesic combinations for the common cold
1. Analgesics [therapeutic use]; 2. *Common Cold [drug therapy]; 3. Cough; 4. Histamine Antagonists [therapeutic use]; 5. *Nasal Decongestants [therapeutic use]; 6. United States;
MESH terms:
Delayed introduction of progressive enteral feeds to prevent necrotising enterocolitis in very low birth weight infants
1. Enteral Nutrition; 2. *Enterocolitis, Necrotizing [epidemiology, prevention & control]; 3. Fetal Growth Retardation; 4. Infant, Premature; 5. Infant, Very Low Birth Weight;
MESH terms:
Rapid versus slow withdrawal of antiepileptic drugs
1. Anticonvulsants [adverse effects]; 2. *Epilepsy [drug therapy]; 3. *Epilepsy, Generalized [drug therapy]; 4. Quality of Life; 5. Seizures [drug therapy];
MESH terms:
Intermittent prophylactic antibiotics for bronchiectasis
1. Anti-Bacterial Agents [therapeutic use]; 2. Antibiotic Prophylaxis; 3. *Bronchiectasis [drug therapy]; 4. Ciprofloxacin [therapeutic use]; 5. Fluoroquinolones [therapeutic use];
MESH terms:
Orthodontic treatment for crowded teeth in children
1. Dentition, Permanent; 2. *Orthodontic Brackets;
MESH terms:
Orthodontic treatment for posterior crossbites
1. Bias; 2. Dental Care; 3. Dentition, Permanent; 4. Europe; 5. *Malocclusion [therapy];
MESH terms:
Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis
1. Abdominal Pain [drug therapy, etiology]; 2. *Cystic Fibrosis [complications]; 3. *Intestinal Obstruction [etiology, therapy]; 4. Pancreas; 5. Randomized Controlled Trials as Topic;
MESH terms:
Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis
1. Cisapride; 2. Constipation [etiology, prevention & control]; 3. *Cystic Fibrosis [complications]; 4. *Intestinal Obstruction [etiology, prevention & control]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic;
MESH terms:
Transfusion thresholds for guiding red blood cell transfusion
1. *Anemia [therapy]; 2. *Erythrocyte Transfusion; 3. Hematocrit; 4. Hemoglobins; 5. Prospective Studies; 6. Randomized Controlled Trials as Topic;
MESH terms:
Continuous glucose monitoring for the prevention of morbidity and mortality in preterm infants
1. Blood Glucose; 2. *Hypoglycemia [chemically induced, prevention & control]; 3. Infant Mortality; 4. *Infant, Premature; 5. Morbidity; 6. Randomized Controlled Trials as Topic;
MESH terms:
Peer support interventions for parents and carers of children with complex needs
1. Adaptation, Psychological; 2. *Caregivers; 3. Mental Health; 4. Parents; 5. *Quality of Life;
MESH terms:
Nifedipine for primary dysmenorrhoea
1. Anti-Inflammatory Agents, Non-Steroidal [therapeutic use]; 2. *Dysmenorrhea [drug therapy]; 3. Menstruation; 4. *Nifedipine [therapeutic use]; 5. Pelvic Pain [drug therapy];
MESH terms:
Autogenic drainage for airway clearance in cystic fibrosis
1. *Cystic Fibrosis [therapy]; 2. Drainage, Postural; 3. Oxygen Saturation; 4. Physical Therapy Modalities; 5. Quality of Life;
MESH terms:
Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis
1. Anti-Bacterial Agents [adverse effects]; 2. *Burkholderia cepacia; 3. *Cystic Fibrosis [complications, drug therapy]; 4. Cystic Fibrosis Transmembrane Conductance Regulator; 5. Persistent Infection; 6. Randomized Controlled Trials as Topic;
MESH terms:
Chemotherapy for second‐stage human African trypanosomiasis: drugs in use
1. *Antiprotozoal Agents [adverse effects]; 2. Nifurtimox [adverse effects]; 3. *Pharmaceutical Preparations; 4. Randomized Controlled Trials as Topic; 5. Trypanosoma brucei gambiense; 6. *Trypanosomiasis, African [drug therapy];
MESH terms:
Antibiotics for treatment of sore throat in children and adults
1. Anti-Bacterial Agents [therapeutic use]; 2. Fever [drug therapy]; 3. *Otitis Media [drug therapy]; 4. Pain [drug therapy]; 5. *Pharyngitis [drug therapy];
MESH terms:
Pharmacological treatment for psychotic depression
1. Antidepressive Agents [therapeutic use]; 2. Depression [drug therapy]; 3. *Depressive Disorder, Major [drug therapy]; 4. *Psychotic Disorders [drug therapy]; 5. Systematic Reviews as Topic;
MESH terms:
Carisbamate add‐on therapy for drug‐resistant focal epilepsy
1. Anticonvulsants [therapeutic use]; 2. Carbamates; 3. *Drug Resistant Epilepsy [drug therapy]; 4. Drug Therapy, Combination; 5. *Epilepsies, Partial [drug therapy]; 6. *Pharmaceutical Preparations; 7. Randomized Controlled Trials as Topic;
MESH terms:
Parenteral versus enteral fluid therapy for children hospitalised with bronchiolitis
1. *Bronchiolitis [therapy]; 2. Enteral Nutrition; 3. Fluid Therapy; 4. Intubation, Gastrointestinal; 5. Length of Stay; 6. Randomized Controlled Trials as Topic;
MESH terms:
Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline
1. Adrenal Cortex Hormones [therapeutic use]; 2. *Antioxidants [therapeutic use]; 3. Forced Expiratory Volume; 4. *Muscular Dystrophy, Duchenne [complications, drug therapy]; 5. Vital Capacity;
MESH terms:
Nasal continuous positive airway pressure levels for the prevention of morbidity and mortality in preterm infants
1. *Bronchopulmonary Dysplasia; 2. *Continuous Positive Airway Pressure; 3. Infant, Premature; 4. Morbidity; 5. Respiration, Artificial;
MESH terms:
Topiramate for juvenile myoclonic epilepsy
1. Anticonvulsants [adverse effects]; 2. *Myoclonic Epilepsy, Juvenile [drug therapy]; 3. Randomized Controlled Trials as Topic; 4. Seizures [drug therapy]; 5. Topiramate [adverse effects]; 6. Valproic Acid [adverse effects];
MESH terms:
Non‐corticosteroid adjuvant therapies for acute bacterial meningitis
1. Acetaminophen; 2. Adrenal Cortex Hormones [therapeutic use]; 3. Anti-Bacterial Agents [therapeutic use]; 4. *Hearing Loss; 5. *Meningitis, Bacterial [drug therapy];
MESH terms:
Vaccines for measles, mumps, rubella, and varicella in children
1. *Chickenpox [prevention & control]; 2. *Measles [prevention & control]; 3. Measles-Mumps-Rubella Vaccine [adverse effects]; 4. *Mumps [prevention & control]; 5. *Rubella [prevention & control];
MESH terms:
Macrolides versus placebo for chronic asthma
1. Anti-Bacterial Agents [adverse effects]; 2. *Asthma [drug therapy]; 3. Disease Progression; 4. Macrolides [therapeutic use]; 5. *Quality of Life;
MESH terms:
Vitamin C supplementation for prevention and treatment of pneumonia
1. Ascorbic Acid [therapeutic use]; 2. Dietary Supplements; 3. Hospitalization; 4. *Pneumonia [drug therapy, prevention & control]; 5. *Vitamins [therapeutic use];
MESH terms:
Vaccines for preventing rotavirus diarrhoea: vaccines in use
1. Child Mortality; 2. Diarrhea [prevention & control]; 3. *Intussusception; 4. *Rotavirus; 5. *Rotavirus Infections [prevention & control];
MESH terms:
Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children
1. Hospitalization; 2. Length of Stay; 3. Palivizumab [therapeutic use]; 4. *Respiratory Syncytial Virus Infections [prevention & control]; 5. Respiratory Syncytial Viruses;
MESH terms:
Late (≥ 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants
1. Adrenal Cortex Hormones [adverse effects]; 2. Anti-Inflammatory Agents [adverse effects]; 3. *Bronchopulmonary Dysplasia [prevention & control]; 4. Dexamethasone [therapeutic use]; 5. Drug Administration Schedule; 6. Glucocorticoids [adverse effects]; 7. Infant, Premature;
MESH terms:
Decision coaching for people making healthcare decisions
1. Anxiety; 2. Family; 3. Health Personnel [education]; 4. *Mentoring; 5. Patient Participation;
MESH terms:
Antiepileptic drugs for seizure control in people with neurocysticercosis
1. *Anticonvulsants [therapeutic use]; 2. *Neurocysticercosis [complications, drug therapy]; 3. Quality of Life; 4. Randomized Controlled Trials as Topic; 5. *Seizures;
MESH terms:
Phototherapy for atopic eczema
1. *Dermatitis, Atopic [drug therapy]; 2. *Eczema; 3. Phototherapy; 4. Quality of Life; 5. *Ultraviolet Therapy;
MESH terms:
Intermittent catheter techniques, strategies and designs for managing long‐term bladder conditions
1. Catheters, Indwelling; 2. Urinary Bladder; 3. Urinary Catheterization [adverse effects]; 4. *Urinary Incontinence; 5. *Urinary Tract Infections [etiology, prevention & control];
MESH terms:
Avoidance of bottles during the establishment of breastfeeds in preterm infants
1. *Breast Feeding; 2. Enteral Nutrition; 3. *Infant, Premature; 4. Length of Stay; 5. Milk, Human;
MESH terms:
Early (< 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants
1. Adrenal Cortex Hormones [adverse effects]; 2. Anti-Inflammatory Agents; 3. *Bronchopulmonary Dysplasia [prevention & control]; 4. Dexamethasone [therapeutic use]; 5. Glucocorticoids [adverse effects]; 6. Infant, Premature;
MESH terms:
Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents, for people with asthma
1. *Anti-Asthmatic Agents [therapeutic use]; 2. *Asthma [drug therapy]; 3. Disease Progression; 4. Immunoglobulin E; 5. Interleukin-13 [therapeutic use]; 6. Interleukin-4 [therapeutic use]; 7. Interleukin-5 [therapeutic use]; 8. Quality of Life;
MESH terms:
Prophylactic or very early initiation of continuous positive airway pressure (CPAP) for preterm infants
1. *Bronchopulmonary Dysplasia [epidemiology, prevention & control]; 2. *Continuous Positive Airway Pressure; 3. Infant, Premature; 4. Infant, Very Low Birth Weight; 5. Intermittent Positive-Pressure Ventilation;
MESH terms:
Provision of folic acid for reducing arsenic toxicity in arsenic‐exposed children and adults
1. *Arsenic; 2. Creatine; 3. Dietary Supplements; 4. Folic Acid; 5. Food, Fortified;
MESH terms:
Materials for retrograde filling in root canal therapy
1. Crowns; 2. *Glass Ionomer Cements; 3. *Root Canal Therapy;
MESH terms:
Pharmacotherapy for trichotillomania
1. Antidepressive Agents, Tricyclic [therapeutic use]; 2. *Antipsychotic Agents [therapeutic use]; 3. Clomipramine; 4. Selective Serotonin Reuptake Inhibitors; 5. *Trichotillomania [drug therapy];
MESH terms:
Sulthiame monotherapy for epilepsy
1. Anticonvulsants [therapeutic use]; 2. *Epilepsy [drug therapy]; 3. Quality of Life; 4. Randomized Controlled Trials as Topic; 5. *Thiazines [therapeutic use];
MESH terms:
Treatments for seizures in catamenial (menstrual‐related) epilepsy
1. Anticonvulsants [therapeutic use]; 2. *Epilepsy [drug therapy]; 3. Fatigue [drug therapy]; 4. *Menstruation; 5. Randomized Controlled Trials as Topic; 6. Seizures [drug therapy];
MESH terms:
Non‐pharmacological interventions for stuttering in children six years and younger
1. Communication; 2. Emotions; 3. Parents; 4. *Stuttering [therapy]; 5. Telephone;
MESH terms:
Behavioural and cognitive behavioural therapy for obsessive compulsive disorder (OCD) in individuals with autism spectrum disorder (ASD)
1. Anxiety [therapy]; 2. *Autism Spectrum Disorder [complications, therapy]; 3. Behavior Therapy; 4. *Cognitive Behavioral Therapy; 5. *Obsessive-Compulsive Disorder [complications, therapy];
MESH terms:
Vitamin D supplementation for chronic liver diseases in adults
1. Dietary Supplements; 2. *Hepatitis C, Chronic; 3. Quality of Life; 4. Vitamin D;
MESH terms:
Recombinant growth hormone therapy for cystic fibrosis in children and young adults
1. *Cystic Fibrosis [complications, drug therapy]; 2. *Diabetes Mellitus; 3. Growth Hormone; 4. *Human Growth Hormone; 5. Quality of Life;
MESH terms:
Heliox for croup in children
1. Airway Obstruction [etiology, *therapy]; 2. Airway Resistance [drug effects]; 3. Croup [complications, drug therapy, *therapy]; 4. Helium [*administration & dosage, therapeutic use]; 5. Oxygen [*administration & dosage, therapeutic use]; 6. Oxygen Inhalation Therapy [methods]; 7. Randomized Controlled Trials as Topic; 8. Treatment Outcome;
MESH terms:
Chloral hydrate as a sedating agent for neurodiagnostic procedures in children
1. Chloral Hydrate [*administration & dosage, adverse effects]; 2. *Diagnostic Techniques, Neurological; 3. Hydroxyzine [administration & dosage]; 4. Hypnotics and Sedatives [*administration & dosage, adverse effects]; 5. Midazolam [administration & dosage, adverse effects]; 6. Pentobarbital [administration & dosage];
MESH terms:
Direct composite resin fillings versus amalgam fillings for permanent posterior teeth
1. Bias; 2. Composite Resins [*therapeutic use]; 3. Dental Amalgam [*therapeutic use]; 4. Dental Caries [*therapy]; 5. Dentition, Permanent; 6. Randomized Controlled Trials as Topic;
MESH terms:
Continuous versus bolus intermittent intragastric tube feeding for preterm and low birth weight infants with gastro‐oesophageal reflux disease
1. Birth Weight; 2. *Enteral Nutrition; 3. *Gastroesophageal Reflux; 4. Infant, Low Birth Weight; 5. Intubation, Gastrointestinal;
MESH terms:
Push versus gravity for intermittent bolus gavage tube feeding of preterm and low birth weight infants
1. Cross-Over Studies; 2. *Enteral Nutrition; 3. *Infant, Low Birth Weight; 4. Infant, Premature; 5. Milk;
MESH terms:
Timing of pancreatic enzyme replacement therapy (PERT) in cystic fibrosis
1. *Cystic Fibrosis [complications, drug therapy]; 2. Enzyme Replacement Therapy; 3. Nutritional Status; 4. Pancreas;
MESH terms:
Schedules for home visits in the early postpartum period
1. Bias; 2. Breast Feeding [statistics & numerical data]; 3. Depression, Postpartum [epidemiology]; 4. Health Services Needs and Demand [statistics & numerical data]; 5. *House Calls [statistics & numerical data]; 6. Infant Mortality; 7. Maternal Mortality; 8. Patient Satisfaction; 9. Perinatal Mortality; 10. Postnatal Care [*organization & administration, statistics & numerical data]; 11. Postpartum Period; 12. Randomized Controlled Trials as Topic; 13. Time Factors;
MESH terms:
Opioid treatment for opioid withdrawal in newborn infants
1. Buprenorphine [therapeutic use]; 2. Chlorpromazine [therapeutic use]; 3. Clonidine [therapeutic use]; 4. Diazepam [therapeutic use]; 5. Hypnotics and Sedatives [therapeutic use]; 6. Methadone [therapeutic use]; 7. Morphine [therapeutic use]; 8. Narcotics [*therapeutic use]; 9. Neonatal Abstinence Syndrome [*drug therapy]; 10. Opioid-Related Disorders [*drug therapy]; 11. Opium [therapeutic use]; 12. Phenobarbital [therapeutic use]; 13. Randomized Controlled Trials as Topic;
MESH terms:
Sunlight for the prevention and treatment of hyperbilirubinemia in term and late preterm neonates
1. Bias; 2. Exchange Transfusion, Whole Blood; 3. Heliotherapy [adverse effects, instrumentation, *methods]; 4. Hyperbilirubinemia, Neonatal [epidemiology, prevention & control, *therapy]; 5. Hyperthermia [epidemiology]; 6. Hypothermia [epidemiology]; 7. Incidence; 8. Infant, Premature; 9. Jaundice, Neonatal [prevention & control, therapy]; 10. Patient Readmission [statistics & numerical data]; 11. Randomized Controlled Trials as Topic; 12. Treatment Failure;
MESH terms:
Bisphosphonate use in children with cerebral palsy
1. Alkaline Phosphatase [blood]; 2. Bias; 3. Bone Density [*drug effects]; 4. Bone Density Conservation Agents [*therapeutic use]; 5. Cerebral Palsy [*complications]; 6. Collagen Type I [blood]; 7. Diphosphonates [*therapeutic use]; 8. Fractures, Spontaneous [prevention & control]; 9. Hydroxycholecalciferols [therapeutic use]; 10. Osteoporosis [blood, *drug therapy]; 11. Peptides [blood]; 12. Randomized Controlled Trials as Topic;
MESH terms:
Ivermectin treatment in humans for reducing malaria transmission
1. Antiparasitic Agents [*administration & dosage, adverse effects, blood]; 2. Bias; 3. Burkina Faso [epidemiology]; 4. Data Analysis; 5. Incidence; 6. Ivermectin [*administration & dosage, adverse effects, blood]; 7. Malaria [epidemiology, prevention & control, *transmission]; 8. *Mosquito Control; 9. Pilot Projects; 10. Prevalence; 11. Randomized Controlled Trials as Topic;
MESH terms:
Altered dietary salt intake for people with chronic kidney disease
1. Antihypertensive Agents [administration & dosage]; 2. Bias; 3. Blood Pressure [*drug effects, physiology]; 4. Body Weight; 5. *Diet, Sodium-Restricted; 6. Edema [prevention & control]; 7. Hypertension [chemically induced, drug therapy]; 8. Randomized Controlled Trials as Topic; 9. Renal Insufficiency, Chronic [*diet therapy]; 10. Selection Bias; 11. Sodium Chloride, Dietary [*administration & dosage, adverse effects];
MESH terms:
Continuous nasogastric milk feeding versus intermittent bolus milk feeding for preterm infants less than 1500 grams
1. Bias; 2. Confidence Intervals; 3. Enteral Nutrition [adverse effects, *methods]; 4. Infant Formula; 5. *Infant, Very Low Birth Weight; 6. Intubation, Gastrointestinal [methods]; 7. Length of Stay; 8. *Milk; 9. *Milk, Human; 10. Randomized Controlled Trials as Topic; 11. Time Factors; 12. Treatment Outcome; 13. Weight Gain;
MESH terms:
Eslicarbazepine acetate add‐on therapy for drug‐resistant focal epilepsy
1. Age Factors; 2. Anticonvulsants [adverse effects, *therapeutic use]; 3. Bias; 4. Dibenzazepines [adverse effects, *therapeutic use]; 5. Drug Resistant Epilepsy [*drug therapy]; 6. Drug Therapy, Combination [methods]; 7. Epilepsies, Partial [*drug therapy]; 8. Intention to Treat Analysis; 9. Randomized Controlled Trials as Topic; 10. Withholding Treatment [statistics & numerical data];
MESH terms:
Prophylactic drug management for febrile seizures in children
1. Anticonvulsants [adverse effects, *therapeutic use]; 2. Antipyretics [adverse effects, *therapeutic use]; 3. Confidence Intervals; 4. Placebos [therapeutic use]; 5. Publication Bias; 6. Randomized Controlled Trials as Topic; 7. Recurrence; 8. Seizures, Febrile [*prevention & control];
MESH terms:
Oral antibiotics for chronic blepharitis
1. Administration, Oral; 2. Anti-Bacterial Agents [*administration & dosage, adverse effects]; 3. Bias; 4. Blepharitis [*drug therapy]; 5. Chronic Disease; 6. Doxycycline [*administration & dosage, adverse effects]; 7. Drug Administration Schedule; 8. Randomized Controlled Trials as Topic;
MESH terms:
Topical azole treatments for otomycosis
1. Administration, Topical; 2. Antifungal Agents [*administration & dosage, adverse effects]; 3. Bias; 4. Clotrimazole [administration & dosage, adverse effects]; 5. Cycloheptanes [administration & dosage, adverse effects]; 6. Fluconazole [administration & dosage, adverse effects]; 7. Imidazoles [administration & dosage, adverse effects]; 8. Miconazole [administration & dosage, adverse effects]; 9. Otomycosis [*drug therapy]; 10. Placebos [therapeutic use]; 11. Randomized Controlled Trials as Topic; 12. Treatment Outcome;
MESH terms:
New generation antidepressants for depression in children and adolescents: a network meta‐analysis
1. Antidepressive Agents [adverse effects, *therapeutic use]; 2. Bias; 3. Citalopram [therapeutic use]; 4. Depressive Disorder, Major [*drug therapy, psychology]; 5. Desvenlafaxine Succinate [therapeutic use]; 6. Duloxetine Hydrochloride [therapeutic use]; 7. Fluoxetine [therapeutic use]; 8. Mirtazapine [therapeutic use]; 9. Network Meta-Analysis; 10. Paroxetine [therapeutic use]; 11. Sertraline [therapeutic use]; 12. Suicidal Ideation; 13. Venlafaxine Hydrochloride [therapeutic use]; 14. Vilazodone Hydrochloride [therapeutic use]; 15. Vortioxetine [therapeutic use];
MESH terms:
Piperonyl butoxide (PBO) combined with pyrethroids in insecticide‐treated nets to prevent malaria in Africa
1. Africa [epidemiology]; 2. Culicidae; 3. Drug Combinations; 4. Feeding Behavior; 5. Insecticide Resistance [*drug effects]; 6. *Insecticide-Treated Bednets; 7. Malaria [epidemiology, *prevention & control]; 8. Mortality; 9. Mosquito Control [*methods]; 10. *Pesticide Synergists; 11. *Piperonyl Butoxide; 12. *Pyrethrins; 13. Randomized Controlled Trials as Topic;
MESH terms:
Internet‐based cognitive and behavioural therapies for post‐traumatic stress disorder (PTSD) in adults
1. Bias; 2. Cognitive Behavioral Therapy [*methods]; 3. *Internet-Based Intervention; 4. Randomized Controlled Trials as Topic; 5. Stress Disorders, Post-Traumatic [*therapy];
MESH terms:
Sedatives for opioid withdrawal in newborn infants
1. Bias; 2. Chlorpromazine [therapeutic use]; 3. Clonidine [therapeutic use]; 4. Diazepam [therapeutic use]; 5. Hypnotics and Sedatives [*therapeutic use]; 6. Narcotics [therapeutic use]; 7. Neonatal Abstinence Syndrome [*drug therapy]; 8. Opioid-Related Disorders [*drug therapy]; 9. Phenobarbital [therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Treatment Outcome;
MESH terms:
Antibiotic regimens for early‐onset neonatal sepsis
1. Anti-Bacterial Agents [adverse effects, *therapeutic use]; 2. Bias; 3. Cause of Death; 4. Neonatal Sepsis [*drug therapy]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Pharmacological and surgical interventions for the treatment of gastro‐oesophageal reflux in adults and children with asthma
1. Acute Disease; 2. Anti-Asthmatic Agents [therapeutic use]; 3. Asthma [*complications, drug therapy]; 4. Cisapride [therapeutic use]; 5. Disease Progression; 6. Forced Expiratory Volume [drug effects]; 7. Gastroesophageal Reflux [complications, *drug therapy, *surgery]; 8. Histamine Antagonists [therapeutic use]; 9. Peak Expiratory Flow Rate; 10. Placebos [therapeutic use]; 11. Proton Pump Inhibitors; 12. Quality of Life; 13. Randomized Controlled Trials as Topic;
MESH terms:
Rubber dam isolation for restorative treatment in dental patients
1. Bias; 2. Dental Atraumatic Restorative Treatment [*instrumentation]; 3. Randomized Controlled Trials as Topic; 4. *Rubber Dams; 5. Treatment Outcome;
MESH terms:
Surfactant therapy via thin catheter in preterm infants with or at risk of respiratory distress syndrome
1. Bias; 2. *Catheters; 3. *Infant, Premature; 4. *Intubation, Intratracheal; 5. Randomized Controlled Trials as Topic; 6. Respiratory Distress Syndrome, Newborn [etiology, *therapy]; 7. Risk; 8. Surface-Active Agents [*administration & dosage];
MESH terms:
Topical emollient for preventing infection in preterm infants
1. Administration, Topical; 2. Bacterial Infections [mortality, *prevention & control]; 3. Bias; 4. Cross Infection [mortality, *prevention & control]; 5. Dermatitis [*prevention & control]; 6. Emollients [*therapeutic use]; 7. Infant, Extremely Premature; 8. Infant, Premature; 9. Infant, Premature, Diseases [*prevention & control]; 10. Mycoses [mortality, *prevention & control]; 11. Ointments [therapeutic use]; 12. Randomized Controlled Trials as Topic; 13. Skin Care;
MESH terms:
Paying for performance to improve the delivery of health interventions in low‐ and middle‐income countries
1. Bias; 2. Controlled Before-After Studies; 3. *Developing Countries; 4. Interrupted Time Series Analysis; 5. Non-Randomized Controlled Trials as Topic; 6. Quality Improvement [*economics, standards]; 7. Quality of Health Care [economics, standards]; 8. *Reimbursement, Incentive;
MESH terms:
Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure
1. Anticonvulsants [adverse effects, *therapeutic use]; 2. Bias; 3. Placebos [therapeutic use]; 4. Randomized Controlled Trials as Topic; 5. Recurrence; 6. Remission Induction; 7. Risk; 8. Secondary Prevention; 9. Seizures [complications, *drug therapy, mortality]; 10. Time Factors; 11. *Time-to-Treatment; 12. Watchful Waiting;
MESH terms:
Rapid versus standard antimicrobial susceptibility testing to guide treatment of bloodstream infection
1. Anti-Bacterial Agents [*therapeutic use]; 2. Bias; 3. Microbial Sensitivity Tests [*methods]; 4. Odds Ratio; 5. Randomized Controlled Trials as Topic; 6. Sepsis [*drug therapy, microbiology, mortality]; 7. Time-to-Treatment;
MESH terms:
Drug therapies for reducing gastric acidity in people with cystic fibrosis
1. Abdominal Pain [drug therapy]; 2. Cystic Fibrosis [*complications, drug therapy]; 3. Dietary Fats [pharmacokinetics]; 4. Gastric Acid [*metabolism]; 5. Gastrointestinal Agents [therapeutic use]; 6. Histamine H2 Antagonists [*therapeutic use]; 7. Intestinal Absorption [drug effects]; 8. Pancreas [enzymology]; 9. Proton Pump Inhibitors [*therapeutic use]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Cough augmentation techniques for people with chronic neuromuscular disorders
1. Bias; 2. Chronic Disease; 3. Cough [*physiopathology]; 4. Disease Progression; 5. Hospitalization [*statistics & numerical data]; 6. Insufflation [methods]; 7. Mucociliary Clearance [*physiology]; 8. Neuromuscular Diseases [*complications]; 9. Patient Satisfaction; 10. Quality of Life; 11. Respiration; 12. Respiration Disorders [etiology];
MESH terms:
Antidepressants for people with epilepsy and depression
1. Antidepressive Agents [adverse effects, *therapeutic use]; 2. Bias; 3. Cognitive Behavioral Therapy; 4. Depression [*drug therapy, etiology]; 5. Epilepsy [chemically induced, *drug therapy, psychology]; 6. Non-Randomized Controlled Trials as Topic; 7. Prospective Studies; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Selective Serotonin Reuptake Inhibitors [adverse effects, therapeutic use];
MESH terms:
Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events
1. Administration, Inhalation; 2. Anti-Asthmatic Agents [administration & dosage, *adverse effects]; 3. Asthma [*drug therapy, mortality]; 4. Beclomethasone [administration & dosage, adverse effects]; 5. Bronchodilator Agents [administration & dosage, adverse effects]; 6. Budesonide [administration & dosage, adverse effects]; 7. Chronic Disease; 8. Drug Therapy, Combination [adverse effects]; 9. Fluticasone [administration & dosage, adverse effects]; 10. Formoterol Fumarate [*administration & dosage, adverse effects]; 11. Glucocorticoids [administration & dosage, *adverse effects]; 12. Mometasone Furoate [administration & dosage, adverse effects]; 13. Randomized Controlled Trials as Topic; 14. Salmeterol Xinafoate [*administration & dosage, adverse effects];
MESH terms:
Anti‐seizure medications for Lennox‐Gastaut syndrome
1. Age of Onset; 2. Anticonvulsants [administration & dosage, adverse effects]; 3. Cannabidiol [administration & dosage, adverse effects]; 4. Cinnamates [administration & dosage, adverse effects]; 5. Clobazam [administration & dosage]; 6. Electroencephalography; 7. Felbamate [administration & dosage]; 8. Lamotrigine [administration & dosage]; 9. Lennox Gastaut Syndrome [*drug therapy]; 10. Placebos [therapeutic use]; 11. Randomized Controlled Trials as Topic; 12. Topiramate [administration & dosage]; 13. Triazoles [administration & dosage]; 14. Wakefulness [physiology];
MESH terms:
Circumcision devices versus standard surgical techniques in adolescent and adult male circumcisions
1. Bias; 2. Circumcision, Male [adverse effects, *instrumentation, *methods]; 3. Operative Time; 4. Pain, Postoperative [epidemiology]; 5. Patient Preference [statistics & numerical data]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Lung recruitment manoeuvres for reducing mortality and respiratory morbidity in mechanically ventilated neonates
1. Bias; 2. Bronchopulmonary Dysplasia [*epidemiology]; 3. Confidence Intervals; 4. Incidence; 5. Infant, Premature; 6. Oxygen [administration & dosage]; 7. Positive-Pressure Respiration [adverse effects, methods]; 8. Respiration, Artificial [*adverse effects, methods, statistics & numerical data]; 9. Respiratory Distress Syndrome, Newborn [*therapy]; 10. Ventilator-Induced Lung Injury [*mortality, prevention & control];
MESH terms:
Dornase alfa for cystic fibrosis
1. Cystic Fibrosis [*drug therapy]; 2. Deoxyribonuclease I [adverse effects, *therapeutic use]; 3. Disease Progression; 4. Expectorants [adverse effects, *therapeutic use]; 5. Forced Expiratory Volume; 6. Mannitol [therapeutic use]; 7. Placebos [therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Recombinant Proteins [adverse effects, therapeutic use]; 10. Saline Solution, Hypertonic [therapeutic use]; 11. Vital Capacity;
MESH terms:
Opioids for newborn infants receiving mechanical ventilation
1. Analgesics, Opioid [adverse effects, *therapeutic use]; 2. Bias; 3. Child Development [drug effects]; 4. Fentanyl [adverse effects, therapeutic use]; 5. Heroin [adverse effects, therapeutic use]; 6. Hypnotics and Sedatives [adverse effects, therapeutic use]; 7. Infant Mortality; 8. Infant, Premature; 9. Midazolam [adverse effects, therapeutic use]; 10. Morphine [adverse effects, therapeutic use]; 11. Pain, Procedural [*prevention & control]; 12. Placebos [therapeutic use]; 13. Randomized Controlled Trials as Topic; 14. Remifentanil [adverse effects, therapeutic use]; 15. Respiration, Artificial [*adverse effects, statistics & numerical data]; 16. Sufentanil [adverse effects, therapeutic use];
MESH terms:
Zinc supplementation for improving pregnancy and infant outcome
1. Bias; 2. *Dietary Supplements; 3. *Infant, Low Birth Weight; 4. Infant, Small for Gestational Age; 5. Perinatal Death [prevention & control]; 6. Pregnancy Outcome; 7. Premature Birth [epidemiology, *prevention & control]; 8. Randomized Controlled Trials as Topic; 9. Stillbirth [epidemiology]; 10. Zinc [*administration & dosage, blood];
MESH terms:
Enteral zinc supplementation for prevention of morbidity and mortality in preterm neonates
1. Bacterial Infections [prevention & control]; 2. Bias; 3. Bronchopulmonary Dysplasia [prevention & control]; 4. Cause of Death; 5. Enteral Nutrition; 6. Enterocolitis, Necrotizing [prevention & control]; 7. Infant Mortality; 8. *Infant, Low Birth Weight [growth & development]; 9. *Infant, Premature [growth & development]; 10. Morbidity; 11. Retinopathy of Prematurity [prevention & control]; 12. Trace Elements [*administration & dosage, deficiency]; 13. Zinc [*administration & dosage, deficiency];
MESH terms:
High versus standard volume enteral feeds to promote growth in preterm or low birth weight infants
1. Enteral Nutrition [adverse effects, *methods]; 2. Enterocolitis, Necrotizing [epidemiology]; 3. Head [growth & development]; 4. *Infant Formula; 5. Infant Nutritional Physiological Phenomena; 6. Infant, Low Birth Weight [*growth & development]; 7. Infant, Premature [*growth & development]; 8. *Milk, Human; 9. Randomized Controlled Trials as Topic; 10. Weight Gain;
MESH terms:
Timing of dornase alfa inhalation for cystic fibrosis
1. Administration, Inhalation; 2. Combined Modality Therapy [methods]; 3. Cystic Fibrosis [*therapy]; 4. Deoxyribonuclease I [*administration & dosage]; 5. Drug Administration Schedule; 6. Forced Expiratory Volume; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Recombinant Proteins [administration & dosage]; 10. Respiratory Therapy [*methods]; 11. Time Factors; 12. Vital Capacity;
MESH terms:
Interventions for self‐harm in children and adolescents
1. Bias; 2. Cognitive Behavioral Therapy [methods]; 3. Confidence Intervals; 4. Depression [therapy]; 5. Dialectical Behavior Therapy [methods]; 6. Family Therapy; 7. *Mentalization; 8. Odds Ratio; 9. Patient Compliance; 10. Psychosocial Intervention [*methods]; 11. Psychotherapy [*methods]; 12. Randomized Controlled Trials as Topic; 13. Recurrence; 14. Secondary Prevention [methods]; 15. Self-Injurious Behavior [prevention & control, psychology, *therapy]; 16. Suicidal Ideation; 17. Treatment Outcome;
MESH terms:
High‐flow nasal cannulae for respiratory support in adult intensive care patients
1. Acute Disease; 2. Barotrauma [epidemiology]; 3. Bias; 4. Critical Care [*methods]; 5. Hospital Mortality; 6. Intubation [adverse effects, instrumentation, *methods]; 7. Length of Stay; 8. Masks; 9. Nasal Mucosa [injuries]; 10. Noninvasive Ventilation [methods]; 11. Oxygen Inhalation Therapy [adverse effects, instrumentation, *methods]; 12. Patient Reported Outcome Measures; 13. Pneumonia [epidemiology]; 14. Randomized Controlled Trials as Topic; 15. Respiration, Artificial [adverse effects]; 16. Respiratory Insufficiency [*therapy]; 17. Treatment Failure;
MESH terms:
(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus
1. Bias; 2. Confidence Intervals; 3. Diabetes Mellitus, Type 1 [blood, *drug therapy, mortality]; 4. Hypoglycemia [chemically induced, mortality]; 5. Hypoglycemic Agents [adverse effects, *therapeutic use]; 6. Insulin Detemir [adverse effects, *therapeutic use]; 7. Insulin Glargine [adverse effects, *therapeutic use]; 8. Insulin, Isophane [adverse effects, *therapeutic use]; 9. Insulin, Long-Acting [adverse effects, *therapeutic use]; 10. Myocardial Infarction [chemically induced, mortality]; 11. Quality of Life; 12. Randomized Controlled Trials as Topic; 13. Stroke [chemically induced, mortality];
MESH terms:
Interventions for bacterial folliculitis and boils (furuncles and carbuncles)
1. Anti-Bacterial Agents [*therapeutic use]; 2. Anti-Infective Agents, Local [therapeutic use]; 3. Bias; 4. Carbuncle [drug therapy]; 5. Furunculosis [*drug therapy]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Antibiotics to prevent complications following tooth extractions
1. Anti-Bacterial Agents [adverse effects, *therapeutic use]; 2. *Antibiotic Prophylaxis [adverse effects]; 3. Bacterial Infections [prevention & control]; 4. Bias; 5. Controlled Clinical Trials as Topic; 6. Dry Socket [prevention & control]; 7. Molar, Third [*surgery]; 8. Pain, Postoperative [prevention & control]; 9. Postoperative Complications [*prevention & control]; 10. Tooth Extraction [*adverse effects]; 11. Tooth, Impacted [*surgery];
MESH terms:
Patient and lay carer education for preventing pressure ulceration in at‐risk populations
1. Caregivers [*education]; 2. Confidence Intervals; 3. Health Facilities [statistics & numerical data]; 4. Patient Education as Topic [*methods]; 5. Pressure Ulcer [epidemiology, *prevention & control]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Risk; 9. Skin Care; 10. Spinal Cord Injuries [complications]; 11. Wound Healing;
MESH terms:
Fluid restriction in the management of transient tachypnea of the newborn
1. Bias; 2. Continuous Positive Airway Pressure [statistics & numerical data]; 3. Fluid Therapy [*methods]; 4. Hyperbilirubinemia [epidemiology]; 5. Hypernatremia [epidemiology]; 6. Hypoglycemia [epidemiology]; 7. Infant, Premature; 8. Length of Stay [statistics & numerical data]; 9. Noninvasive Ventilation [statistics & numerical data]; 10. Oxygen Inhalation Therapy [*statistics & numerical data]; 11. Randomized Controlled Trials as Topic; 12. Respiration, Artificial [statistics & numerical data]; 13. Term Birth; 14. Transient Tachypnea of the Newborn [*therapy]; 15. Weight Loss;
MESH terms:
The effectiveness and adverse effects of D‐cycloserine compared with placebo on social and communication skills in individuals with autism spectrum disorder
1. Autism Spectrum Disorder [*drug therapy]; 2. *Communication; 3. Cycloserine [adverse effects, *therapeutic use]; 4. Indiana; 5. Multicenter Studies as Topic; 6. Ohio; 7. Patient Dropouts [statistics & numerical data]; 8. Placebos [therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. *Social Skills; 11. Stereotyped Behavior [drug effects];
MESH terms:
Topical versus systemic antibiotics for chronic suppurative otitis media
1. Administration, Topical; 2. Aminoglycosides [administration & dosage]; 3. Amoxicillin-Potassium Clavulanate Combination [administration & dosage]; 4. Anti-Bacterial Agents [*administration & dosage]; 5. Bias; 6. Chronic Disease; 7. Ofloxacin [administration & dosage]; 8. Otitis Media, Suppurative [*drug therapy]; 9. Quinolones [administration & dosage]; 10. Randomized Controlled Trials as Topic; 11. Time Factors;
MESH terms:
Salbutamol for transient tachypnea of the newborn
1. Adrenergic beta-2 Receptor Agonists [*therapeutic use]; 2. Albuterol [*therapeutic use]; 3. Continuous Positive Airway Pressure [statistics & numerical data]; 4. Intermittent Positive-Pressure Ventilation [statistics & numerical data]; 5. Length of Stay [statistics & numerical data]; 6. Nebulizers and Vaporizers; 7. Oxygen Inhalation Therapy [statistics & numerical data]; 8. Randomized Controlled Trials as Topic; 9. Time Factors; 10. Transient Tachypnea of the Newborn [*drug therapy];
MESH terms:
Systemic antibiotics for chronic suppurative otitis media
1. Amoxicillin [therapeutic use]; 2. Anti-Bacterial Agents [adverse effects]; 3. Ciprofloxacin [therapeutic use]; 4. *Otitis Media, Suppurative [complications]; 5. *Ototoxicity; 6. Pain [drug therapy]; 7. Persistent Infection;
MESH terms:
Urgent‐start peritoneal dialysis versus haemodialysis for people with chronic kidney disease
1. Bacteremia [epidemiology, prevention & control]; 2. Bias; 3. Catheter-Related Infections [epidemiology, prevention & control]; 4. *Central Venous Catheters; 5. Emergency Treatment [adverse effects, instrumentation, *methods, mortality]; 6. Hospitalization [statistics & numerical data]; 7. Observational Studies as Topic [statistics & numerical data]; 8. Peritoneal Dialysis [adverse effects, instrumentation, methods, mortality]; 9. Peritonitis [epidemiology]; 10. Renal Dialysis [adverse effects, instrumentation, *methods, mortality]; 11. Renal Insufficiency, Chronic [mortality, *therapy]; 12. *Time-to-Treatment;
MESH terms:
Beta‐blockers versus placebo or no intervention for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
1. Adrenergic beta-Antagonists [*adverse effects, therapeutic use]; 2. Chronic Disease; 3. Esophageal and Gastric Varices [*complications]; 4. Gastrointestinal Hemorrhage [etiology, *prevention & control]; 5. Hypertension, Portal [complications]; 6. Liver Diseases [*complications]; 7. Placebos [therapeutic use]; 8. *Portal Vein; 9. Primary Prevention [methods]; 10. Venous Thrombosis [*complications];
MESH terms:
Surgical interventions for the early management of Bell's palsy
1. Bell Palsy [*surgery]; 2. Decompression, Surgical [*methods]; 3. Facial Nerve [*surgery]; 4. Randomized Controlled Trials as Topic; 5. Time-to-Treatment;
MESH terms:
Band ligation versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in children and adolescents with chronic liver disease or portal vein thrombosis
1. Chronic Disease; 2. Esophageal and Gastric Varices [*complications]; 3. Feasibility Studies; 4. Gastrointestinal Hemorrhage [epidemiology, etiology, *prevention & control]; 5. Ligation [adverse effects, *methods, mortality]; 6. Liver Diseases [*complications]; 7. *Portal Vein; 8. Primary Prevention [methods]; 9. Venous Thrombosis [*complications];
MESH terms:
Effect of atorvastatin on testosterone levels
1. Androgens [blood]; 2. Androstenedione [blood]; 3. Atorvastatin [adverse effects, *pharmacology]; 4. Bias; 5. Dehydroepiandrosterone Sulfate [blood]; 6. Hydroxymethylglutaryl-CoA Reductase Inhibitors [adverse effects, *pharmacology]; 7. Placebos [pharmacology]; 8. Polycystic Ovary Syndrome [*blood, drug therapy]; 9. Randomized Controlled Trials as Topic; 10. Sex Factors; 11. Sex Hormone-Binding Globulin [analysis, drug effects]; 12. Testosterone [*blood];